NEW STEP BY STEP MAP FOR AZELAPRAG SMALL MOLECULE

The decision follows observations of liver transaminitis with no clinically sizeable signs and symptoms, and with no apparent dose dependence, in a few sufferers from the azelaprag arms of your STRIDES Section two clinical trial for obesity (website link).We are excited about the opportunity to collaborate with BioAge to share Lilly’s knowledge i